User menu

Antivascular therapy for epithelial ovarian cancer

Bibliographic reference Duhoux, François ; Machiels, Jean-Pascal. Antivascular therapy for epithelial ovarian cancer. In: Journal of Oncology, Vol. 2010, p. 372547 [1-16] (2010)
Permanent URL http://hdl.handle.net/2078.1/29006
  1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer Statistics, 2008, 10.3322/ca.2007.0010
  2. Martin Lainie, Schilder Russell, Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition, 10.1200/jco.2007.11.1088
  3. Folkman Judah, Angiogenesis in cancer, vascular, rheumatoid and other disease, 10.1038/nm0195-27
  4. Yoshiji H, The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model, 10.1053/jhep.2001.23312
  5. Hicklin Daniel J., Ellis Lee M., Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis, 10.1200/jco.2005.06.081
  6. Ferrara Napoleone, Gerber Hans-Peter, LeCouter Jennifer, The biology of VEGF and its receptors, 10.1038/nm0603-669
  7. Trinh X B, Tjalma W A A, Vermeulen P B, Van den Eynden G, Van der Auwera I, Van Laere S J, Helleman J, Berns E M J J, Dirix L Y, van Dam P A, The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer, 10.1038/sj.bjc.6604921
  8. Oncology Reports, 15, 831 (2006)
  9. Monk Bradley J., Choi David C., Pugmire Gordon, Burger Robert A., Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer, 10.1016/j.ygyno.2004.12.001
  10. Monk Bradley J., Han Ernest, Josephs-Cowan Carol A., Pugmire Gordon, Burger Robert A., Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer, 10.1016/j.ygyno.2006.05.006
  11. Burger Robert A., Sill Michael W., Monk Bradley J., Greer Benjamin E., Sorosky Joel I., Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study, 10.1200/jco.2007.11.5345
  12. Cannistra Stephen A., Matulonis Ursula A., Penson Richard T., Hambleton Julie, Dupont Jakob, Mackey Howard, Douglas Jeffrey, Burger Robert A., Armstrong Deborah, Wenham Robert, McGuire William, Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer, 10.1200/jco.2007.12.0782
  13. Mabuchi S., Terai Y., Morishige K., Tanabe-Kimura A., Sasaki H., Kanemura M., Tsunetoh S., Tanaka Y., Sakata M., Burger R. A., Kimura T., Ohmichi M., Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model, 10.1158/1078-0432.ccr-08-0243
  14. Jain R. K., Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy, 10.1126/science.1104819
  15. Frederick Peter J., Straughn J. Michael, Alvarez Ronald D., Buchsbaum Donald J., Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer, 10.1016/j.ygyno.2009.01.008
  16. Wright Jason D., Hagemann Andrea, Rader Janet S., Viviano Dana, Gibb Randall K., Norris Lori, Mutch David G., Powell Matthew A., Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma : A retrospective analysis, 10.1002/cncr.21969
  17. Richardson Debra L., Backes Floor J., Seamon Leigh G., Zanagnolo Vanna, O'Malley David M., Cohn David E., Fowler Jeffrey M., Copeland Larry J., Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer, 10.1016/j.ygyno.2008.08.011
  18. Cohn David E., Valmadre Sue, Resnick Kimberly E., Eaton Lynne A., Copeland Larry J., Fowler Jeffrey M., Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer, 10.1016/j.ygyno.2006.01.030
  19. Bocci G., Francia G., Man S., Lawler J., Kerbel R. S., Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy, 10.1073/pnas.2135406100
  20. Cancer Research, 60, 1878 (2000)
  21. Kerbel Robert S., Kamen Barton A., The anti-angiogenic basis of metronomic chemotherapy, 10.1038/nrc1369
  22. CHURA J, VANISEGHEM K, DOWNSJR L, CARSON L, JUDSON P, Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer☆, 10.1016/j.ygyno.2007.07.017
  23. Garcia Agustin A., Hirte Hal, Fleming Gini, Yang Dongyun, Tsao-Wei Denice D., Roman Lynda, Groshen Susan, Swenson Steve, Markland Frank, Gandara David, Scudder Sidney, Morgan Robert, Chen Helen, Lenz Heinz-Josef, Oza Amit M., Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia, 10.1200/jco.2007.12.1939
  24. Yap Timothy A., Carden Craig P., Kaye Stan B., Beyond chemotherapy: targeted therapies in ovarian cancer, 10.1038/nrc2583
  25. Bartlett JMS, Langdon SP, Simpson BJB, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams ARW, Lessells AM, Macleod KG, Smyth JF, Miller WR, The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer, 10.1038/bjc.1996.53
  26. Psyrri A., Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer, 10.1158/1078-0432.ccr-05-1436
  27. Tabernero J., The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents, 10.1158/1541-7786.mcr-06-0404
  28. Posadas Edwin M., Liel Meghan S., Kwitkowski Virginia, Minasian Lori, Godwin Andrew K., Hussain Mahrukh M., Espina Virginia, Wood Bradford J., Steinberg Seth M., Kohn Elise C., A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer, 10.1002/cncr.22545
  29. Gordon Michael S., Matei Daniela, Aghajanian Carol, Matulonis Ursula A., Brewer Molly, Fleming Gini F., Hainsworth John D., Garcia Agustin A., Pegram Mark D., Schilder Russell J., Cohn David E., Roman Lynda, Derynck Mika K., Ng Kimmie, Lyons Benjamin, Allison David E., Eberhard David A., Pham Thinh Q., Dere Randall C., Karlan Beth Y., Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status, 10.1200/jco.2005.05.4221
  30. Nimeiri Halla S., Oza Amit M., Morgan Robert J., Friberg Gregory, Kasza Kristen, Faoro Leonardo, Salgia Ravi, Stadler Walter M., Vokes Everett E., Fleming Gini F., Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia, 10.1016/j.ygyno.2008.02.009
  31. Azad Nilofer S., Posadas Edwin M., Kwitkowski Virginia E., Steinberg Seth M., Jain Lokesh, Annunziata Christina M., Minasian Lori, Sarosy Gisele, Kotz Herbert L., Premkumar Ahalya, Cao Liang, McNally Deborah, Chow Catherine, Chen Helen X., Wright John J., Figg William D., Kohn Elise C., Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity, 10.1200/jco.2007.10.8332
  32. Treins Caroline, Giorgetti-Peraldi Sophie, Murdaca Joseph, Semenza Gregg L., Van Obberghen Emmanuel, Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway, 10.1074/jbc.m204152200
  33. Huynh H., Teo C. C. M., Soo K. C., Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer, 10.1158/1535-7163.mct-07-0237
  34. Van Cutsem E., Rivera F., Berry S., Kretzschmar A., Michael M., DiBartolomeo M., Mazier M.-A., Canon J.-L., Georgoulias V., Peeters M., Bridgewater J., Cunningham D., , Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study, 10.1093/annonc/mdp233
  35. WRIGHT J.D., SECORD A.A., NUMNUM T.M., ROCCONI R.P., POWELL M.A., BERCHUCK A., ALVAREZ R.D., GIBB R.K., TRINKAUS K., RADER J.S., MUTCH D.G., A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer, 10.1111/j.1525-1438.2007.01027.x
  36. SIMPKINS F, BELINSON J, ROSE P, Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening, 10.1016/j.ygyno.2007.06.004
  37. Gordon Michael S., Cunningham David, Managing Patients Treated with Bevacizumab Combination Therapy, 10.1159/000088481
  38. Burkart Collin M., Grisel Jedidiah J., Hom David B., Spontaneous Nasal Septal Perforation With Antiangiogenic Bevacizumab Therapy : , 10.1097/mlg.0b013e31817c4296
  39. JAISHUEN A., BERRIOS-RIVERA J.P., SIRISABYA N., ZHENG H.G., LI Y., KAVANAGH J.J., Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary, 10.1111/j.1525-1438.2007.01023.x
  40. Clinical Cancer Research, 9, 5721 (2003)
  41. Hu L., Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer Model, 10.1158/1078-0432.ccr-05-0910
  42. Journal of Clinical Oncology, 23, 3029 (2005)
  43. Journal of Clinical Oncology, 25, 5508 (2007)
  44. Jayson Gordon C., Mulatero Clive, Ranson Malcolm, Zweit Jamal, Jackson Alan, Broughton Lynn, Wagstaff John, Hakansson Leif, Groenewegen Gerard, Lawrance Jeremy, Tang Meina, Wauk Linda, Levitt Dan, Marreaud Sandrine, Lehmann Frederic F., Herold Manfred, Zwierzina Heinz, Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer, 10.1016/j.ejca.2004.11.021
  45. Journal of Clinical Oncology, 26, 5501 (2008)
  46. Miao Hua-Quan, Hu Kun, Jimenez Xenia, Navarro Elizabeth, Zhang Haifan, Lu Dan, Ludwig Dale L., Balderes Paul, Zhu Zhenping, Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2, 10.1016/j.bbrc.2006.04.119
  47. Holtz David O, Krafty Robert T, Mohamed-Hadley Alisha, Zhang Lin, Alagkiozidis Ioannis, Leiby Benjamin, Guo Wensheng, Gimotty Phyllis A, Coukos George, Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer, 10.1186/1479-5876-6-2
  48. Alvarez Ricardo H., Kantarjian Hagop M., Cortes Jorge E., Biology of Platelet-Derived Growth Factor and Its Involvement in Disease, 10.4065/81.9.1241
  49. Östman Arne, Heldin Carl‐Henrik, PDGF Receptors as Targets in Tumor Treatment, Advances in Cancer Research (2007) ISBN:9780120066971 p.247-274, 10.1016/s0065-230x(06)97011-0
  50. Cancer Research, 53, 4550 (1993)
  51. Matei D., Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor   and Akt Inactivation, 10.1158/1078-0432.ccr-0754-03
  52. Matei Daniela, Kelich Stephanie, Cao Liyun, Menning Nancy, Emerson Robert E., Rao Jyiannu, Jeng Meei Huey, Sledge George W., PDGF BB induces VEGF secretion in ovarian cancer, 10.4161/cbt.6.12.4976
  53. Coleman Robert L., Broaddus Russell R., Bodurka Diane C., Wolf Judith K., Burke Thomas W., Kavanagh John J., Levenback Charles F., Gershenson David M., Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers, 10.1016/j.ygyno.2005.09.041
  54. ALBERTS D.S., LIU P.Y., WILCZYNSKI S.P., JANG A., MOON J., WARD J.H., BECK J.T., CLOUSER M., MARKMAN M., Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211), 10.1111/j.1525-1438.2007.00882.x
  55. Posadas Edwin M., Kwitkowski Virginia, Kotz Herbert L., Espina Virginia, Minasian Lori, Tchabo Nana, Premkumar Ahalya, Hussain Mahrukh M., Chang Richard, Steinberg Seth M., Kohn Elise C., A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer : A phase II clinical study with proteomic profiling, 10.1002/cncr.22757
  56. Apte S. M., Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma, 10.1158/1078-0432.ccr-1151-3
  57. Matei Daniela, Emerson Robert E., Schilder Jeanne, Menning Nancy, Baldridge Lee Ann, Johnson Cynthia S., Breen Tim, McClean John, Stephens Doyle, Whalen Charles, Sutton Gregory, Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : A Hoosier Oncology Group trial, 10.1002/cncr.23605
  58. Lu Chunhua, Thaker Premal H., Lin Yvonne G., Spannuth Whitney, Landen Charles N., Merritt William M., Jennings Nicholas B., Langley Robert R., Gershenson David M., Yancopoulos George D., Ellis Lee M., Jaffe Robert B., Coleman Robert L., Sood Anil K., Impact of vessel maturation on antiangiogenic therapy in ovarian cancer, 10.1016/j.ajog.2007.12.028
  59. RAUH-HAIN J.A., PENSON R.T., Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma, 10.1111/j.1525-1438.2007.01156.x
  60. Motzer Robert J., Rini Brian I., Bukowski Ronald M., Curti Brendan D., George Daniel J., Hudes Gary R., Redman Bruce G., Margolin Kim A., Merchan Jaime R., Wilding George, Ginsberg Michelle S., Bacik Jennifer, Kim Sindy T., Baum Charles M., Michaelson M. Dror, Sunitinib in Patients With Metastatic Renal Cell Carcinoma, 10.1001/jama.295.21.2516
  61. Torino Francesco, Corsello Salvatore Maria, Longo Raffaele, Barnabei Agnese, Gasparini Giampietro, Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy, 10.1038/nrclinonc.2009.4
  62. Alavi A., Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli, 10.1126/science.1082015
  63. Singer G., Oldt R., Cohen Y., Wang B. G., Sidransky D., Kurman R. J., Shih I.-M., Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma, 10.1093/jnci/95.6.484
  64. Dal Lago L., D'Hondt V., Awada A., Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors, 10.1634/theoncologist.2007-0233
  65. DeGrendele Heather, Chu Edward, Marshall John, Activity of the Raf Kinase Inhibitor BAY 43-9006 in Patients with Advanced Solid Tumors, 10.1016/s1533-0028(11)70463-7
  66. International Journal of Oncology, 16, 445 (2000)
  67. Li C., Kuchimanchi M., Hickman D., Poppe L., Hayashi M., Zhou Y., Subramanian R., Kumar G., Surapaneni S., In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans, 10.1124/dmd.108.025742
  68. Hilberg F., Roth G. J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., Garin-Chesa P., Bader G., Zoephel A., Quant J., Heckel A., Rettig W. J., BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy, 10.1158/0008-5472.can-07-6307
  69. Journal of Clinical Oncology, 27 (2009)
  70. Bagnato Anna, Spinella Francesca, Rosanò Laura, The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin., 10.1139/y08-058
  71. Martin Smollich, Pia Wulfing, The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies, 10.2174/157016107781024082
  72. Cancer Research, 59, 720 (1999)
  73. Cancer Research, 63, 2447 (2003)
  74. Phuphanich S., Carson K. A., Grossman S. A., Lesser G., Olson J., Mikkelsen T., Desideri S., Fisher J. D., , Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma, 10.1215/15228517-2008-013
  75. Growcott James W., Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054 : , 10.1097/cad.0b013e328320791c
  76. Rosano L., Di Castro V., Spinella F., Tortora G., Nicotra M. R., Natali P. G., Bagnato A., Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity, 10.1158/0008-5472.can-07-0883
  77. Rosano L., Di Castro V., Spinella F., Nicotra M. R., Natali P. G., Bagnato A., ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo, 10.1158/1535-7163.mct-07-0151
  78. Kurmasheva R. T., Harwood F. C., Houghton P. J., Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors, 10.1158/1535-7163.mct-06-0646
  79. Mabuchi S., Altomare D. A., Connolly D. C., Klein-Szanto A., Litwin S., Hoelzle M. K., Hensley H. H., Hamilton T. C., Testa J. R., RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer, 10.1158/0008-5472.can-06-4490
  80. Mabuchi S., Altomare D. A., Cheung M., Zhang L., Poulikakos P. I., Hensley H. H., Schilder R. J., Ozols R. F., Testa J. R., RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model, 10.1158/1078-0432.ccr-06-2770
  81. Fleming R.Y.Declan, Ellis Lee M, Parikh Nila U, Liu Wenbiao, Staley Charles A, Gallick Gary E, Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase, 10.1016/s0039-6060(97)90044-1
  82. Summy J. M., AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes, 10.1158/1535-7163.mct-05-0171
  83. Trevino Jose G., Summy Justin M., Gray Michael J., Nilsson Monique B., Lesslie Donald P., Baker Cheryl H., Gallick Gary E., Expression and Activity of Src Regulate Interleukin-8 Expression in Pancreatic Adenocarcinoma Cells: Implications for Angiogenesis, 10.1158/0008-5472.can-04-3858
  84. Mukhopadhyay Debabrata, Tsiokas Leonidas, Zhou Xiao-Mai, Foster David, Brugge Joan S., Sukhatme Vikas P., Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation, 10.1038/375577a0
  85. Han Liz Y., Landen Charles N., Trevino Jose G., Halder Jyotsnabaran, Lin Yvonne G., Kamat Aparna A., Kim Tae-Jin, Merritt William M., Coleman Robert L., Gershenson David M., Shakespeare William C., Wang Yihan, Sundaramoorth Raji, Metcalf Chester A., Dalgarno David C., Sawyer Tomi K., Gallick Gary E., Sood Anil K., Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma, 10.1158/0008-5472.can-06-1410
  86. Landen C. N., Lu C., Han L. Y., Coffman K. T., Bruckheimer E., Halder J., Mangala L. S., Merritt W. M., Lin Y. G., Gao C., Schmandt R., Kamat A. A., Li Y., Thaker P., Gershenson D. M., Parikh N. U., Gallick G. E., Kinch M. S., Sood A. K., Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer, 10.1093/jnci/djj414
  87. Yokoyama Y., Sedgewick G., Ramakrishnan S., Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination, 10.1158/0008-5472.can-07-0172
  88. Journal of Clinical Oncology, 27 (2009)
  89. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis., 10.1073/pnas.91.9.4082
  90. Chan John K., Manuel Michael R., Ciaravino Giuseppe, Cheung Michael K., Husain Amreen, Teng Nelson N.H., Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma, 10.1016/j.ygyno.2006.05.035
  91. Gordinier Mary E., Dizon Don S., Weitzen Sherry, Disilvestro Paul A., Moore Richard G., Granai C.O., Oral Thalidomide as Palliative Chemotherapy in Women with Advanced Ovarian Cancer, 10.1089/jpm.2006.0083
  92. Downs Levi S., Judson Patricia L., Argenta Peter A., Ghebre Rahel, Geller Melissa A., Bliss Robin L., Boente Matthew P., Nahhas William A., Abu-Ghazaleh Samir Z., Chen M. Dwight, Carson Linda F., A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma, 10.1002/cncr.23164
  93. Tsujii Masahiko, Kawano Sunao, Tsuji Shingo, Sawaoka Hitoshi, Hori Masatsugu, DuBois Raymond N, Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells, 10.1016/s0092-8674(00)81433-6
  94. Yokoyama Y., Xin B., Shigeto T., Umemoto M., Kasai-Sakamoto A., Futagami M., Tsuchida S., Al-Mulla F., Mizunuma H., Clofibric acid, a peroxisome proliferator-activated receptor   ligand, inhibits growth of human ovarian cancer, 10.1158/1535-7163.mct-06-0722
  95. Xin Bing, Yokoyama Yoshihito, Shigeto Tatsuhiko, Futagami Masayuki, Mizunuma Hideki, Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers, 10.1002/cncr.22854
  96. Takei Y., Saga Y., Mizukami H., Takayama T., Ohwada M., Ozawa K., Suzuki M., Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice, 10.1158/1535-7163.mct-06-0724
  97. Merritt William M., Lin Yvonne G., Spannuth Whitney A., Fletcher Mavis S., Kamat Aparna A., Han Liz Y., Landen Charles N., Jennings Nicholas, De Geest Koen, Langley Robert R., Villares Gabriel, Sanguino Angela, Lutgendorf Susan K., Lopez-Berestein Gabriel, Bar-Eli Menashe M., Sood Anil K., Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth, 10.1093/jnci/djn024
  98. Weng D. E., A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors, 10.1158/1535-7163.mct-04-0210
  99. WEI F., CAO S., REN X., LIU H., YU J., LI H., HAO X., Efficient antiproliferative and antiangiogenic effects on human ovarian cancer growth by gene transfer of attenuated mutants of Shiga-like toxin I, 10.1111/j.1525-1438.2007.01090.x
  100. Clinical Cancer Research, 7, 3912 (2001)
  101. Hussain Mahrukh M., Kotz Herbert, Minasian Lori, Premkumar Ahalya, Sarosy Gisele, Reed Eddie, Zhai Suoping, Steinberg Seth M., Raggio Miranda, Oliver Vyta Kulpa, Figg William D., Kohn Elise C., Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer, 10.1200/jco.2003.04.136
  102. Tait Catherine R, Jones Pamela F, Angiopoietins in tumours: the angiogenic switch, 10.1002/path.1618
  103. Fukumura Dai, Jain Rakesh K., Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize, 10.1002/jcb.21187
  104. Tozer Gillian M., Kanthou Chryso, Baguley Bruce C., Disrupting tumour blood vessels, 10.1038/nrc1628
  105. Hinnen P, Eskens F A L M, Vascular disrupting agents in clinical development, 10.1038/sj.bjc.6603694
  106. Cancer Research, 62, 7247 (2002)
  107. Kim T. J., Ravoori M., Landen C. N., Kamat A. A., Han L. Y., Lu C., Lin Y. G., Merritt W. M., Jennings N., Spannuth W. A., Langley R., Gershenson D. M., Coleman R. L., Kundra V., Sood A. K., Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma, 10.1158/0008-5472.can-06-4018
  108. Siemann Dietmar W., Mercer Emma, Lepler Sharon, Rojiani Amyn M., Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy, 10.1002/ijc.10316
  109. Cancer Research, 63, 7400 (2003)
  110. Pastorino F., Di Paolo D., Piccardi F., Nico B., Ribatti D., Daga A., Baio G., Neumaier C. E., Brignole C., Loi M., Marimpietri D., Pagnan G., Cilli M., Lepekhin E. A., Garde S. V., Longhi R., Corti A., Allen T. M., Wu J. J., Ponzoni M., Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin, 10.1158/1078-0432.ccr-08-0804
  111. International Journal of Biological Markers, 13, 179 (1998)
  112. Yin Beatrice W.T., Dnistrian Ann, Lloyd Kenneth O., Ovarian cancer antigen CA125 is encoded by theMUC16 mucin gene, 10.1002/ijc.10250
  113. Azad Nilofer S., Annunziata Christina M., Steinberg Seth M., Minasian Lori, Premkumar Ahalya, Chow Catherine, Kotz Herbert L., Kohn Elise C., Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy, 10.1002/cncr.23374
  114. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 10.1016/j.ejca.2008.10.026
  115. Sabir Adeel, Schor-Bardach Rachel, Wilcox Carol J., Rahmanuddin Syed, Atkins Michael B., Kruskal Jonathan B., Signoretti Sabina, Raptopoulos Vassilios D., Goldberg S. Nahum, Perfusion MDCT Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy, 10.2214/ajr.07.2848
  116. American Journal of Pathology, 147, 33 (1995)
  117. Palmer Julia E., Sant Cassia Louis J., Irwin Clive J., Morris Alan G., Rollason Terence P., Prognostic Value of Measurements of Angiogenesis in Serous Carcinoma of the Ovary : , 10.1097/pgp.0b013e318063bed7
  118. Suhonen Kirsi A., Anttila Maarit A., Sillanpää Sari M., Hämäläinen Kirsi M., Saarikoski Seppo V., Juhola Matti, Kosma Veli-Matti, Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer, 10.1016/j.ejca.2007.03.007
  119. True, 10.1054/bjoc.2000.1228
  120. O'Toole S.A., Sheppard B.L., Laios A., O'Leary J.J., McGuinness E.P.J., D'Arcy T., Bonnar J., Potential predictors of chemotherapy response in ovarian cancer—How do we define chemosensitivity?, 10.1016/j.ygyno.2006.08.039
  121. Raspollini M. R., Amunni G., Villanucci A., Baroni G., Boddi V., Taddei G. L., Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma, 10.1111/j.1048-891x.2004.014514.x
  122. Duncan T. J., Al-Attar A., Rolland P., Scott I. V., Deen S., Liu D. T.Y., Spendlove I., Durrant L. G., Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?, 10.1158/1078-0432.ccr-07-1888
  123. Tempfer C, Vascular endothelial growth factor serum concentrations in ovarian cancer, 10.1016/s0029-7844(98)00190-2
  124. Hefler L. A., Mustea A., Konsgen D., Concin N., Tanner B., Strick R., Heinze G., Grimm C., Schuster E., Tempfer C., Reinthaller A., Zeillinger R., Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer, 10.1158/1078-0432.ccr-06-1008
  125. Mendiola Marta, Barriuso Jorge, Redondo Andrés, Mariño-Enríquez Adrián, Madero Rosario, Espinosa Enrique, Vara Juan Ángel Fresno, Sánchez-Navarro Iker, Hernández-Cortes Ginés, Zamora Pilar, Pérez-Fernández Elia, Miguel-Martín María, Suárez Asunción, Palacios José, González-Barón Manuel, Hardisson David, Angiogenesis-Related Gene Expression Profile with Independent Prognostic Value in Advanced Ovarian Carcinoma, 10.1371/journal.pone.0004051
  126. Buckanovich Ronald J., Sasaroli Dimitra, O'Brien-Jenkins Anne, Botbyl Jeffrey, Hammond Rachel, Katsaros Dionysios, Sandaltzopoulos Raphael, Liotta Lance A., Gimotty Phyllis A., Coukos George, Tumor Vascular Proteins As Biomarkers in Ovarian Cancer, 10.1200/jco.2006.08.8583
  127. Strieter Robert M., Burdick Marie D., Mestas Javier, Gomperts Brigitte, Keane Michael P., Belperio John A., Cancer CXC chemokine networks and tumour angiogenesis, 10.1016/j.ejca.2006.01.006
  128. Mizukami Yusuke, Jo Won-Seok, Duerr Eva-Maria, Gala Manish, Li Jingnan, Zhang Xiaobo, Zimmer Michael A, Iliopoulos Othon, Zukerberg Lawrence R, Kohgo Yutaka, Lynch Maureen P, Rueda Bo R, Chung Daniel C, Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells, 10.1038/nm1294
  129. Schultheis A. M., Lurje G., Rhodes K. E., Zhang W., Yang D., Garcia A. A., Morgan R., Gandara D., Scudder S., Oza A., Hirte H., Fleming G., Roman L., Lenz H.-J., Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab, 10.1158/1078-0432.ccr-08-0351
  130. SHAW T, VANDERHYDEN B, AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate, 10.1016/j.ygyno.2006.10.052
  131. Alcázar J. L., Tumor angiogenesis assessed by three-dimensional power Doppler ultrasound in early, advanced and metastatic ovarian cancer: a preliminary study, 10.1002/uog.3804
  132. Thomassin-Naggara Isabelle, Bazot Marc, Daraï Emile, Callard Patrice, Thomassin Jeanne, Cuenod Charles A., Epithelial Ovarian Tumors: Value of Dynamic Contrast-enhanced MR Imaging and Correlation with Tumor Angiogenesis, 10.1148/radiol.2481071120
  133. Nagengast W. B., de Vries E. G., Hospers G. A., Mulder N. H., de Jong J. R., Hollema H., Brouwers A. H., van Dongen G. A., Perk L. R., Lub-de Hooge M. N., In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft, 10.2967/jnumed.107.041301
  134. Wang Hui, Cai Weibo, Chen Kai, Li Zi-Bo, Kashefi Amir, He Lina, Chen Xiaoyuan, A new PET tracer specific for vascular endothelial growth factor receptor 2, 10.1007/s00259-007-0524-0